SCHEMBL5361699

SCHEMBL5361699

Cc1cc(C(F)(F)F)nc(N)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 2/20 1.00
HSP90AB1 P08238 1/20 1.00
KDM4E B2RXH2 6/20 0.50
HSD17B10 Q99714 4/20 0.50
ALDH1A1 P00352 2/20 0.47
PTGS2 P35354 1/20 0.46
ADORA2A P29274 3/20 0.45
ADORA1 P30542 3/20 0.45
GRM4 Q14833 1/20 0.45
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
HTT P42858 1/20 0.42
ATM Q13315 1/20 0.42
NUDT1 P36639 1/20 0.42
CYP1A2 P05177 1/20 0.40
CYP2C19 P33261 1/20 0.40
HPGD P15428 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
TSHR P16473 1/20 0.39
CRHBP P24387 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10900625 0.84 HSP90AA1 (0.71) HSP90AA1HSP90AB1KDM4EHSD17B10ALDH1A1
SCHEMBL5367782 0.83 HSP90AA1 (0.71) HSP90AA1HSP90AB1KDM4EHSD17B10ALDH1A1
SCHEMBL15429553 0.80 HSP90AA1 (0.67) HSP90AA1HSP90AB1KDM4EHSD17B10NUDT1
SCHEMBL18299043 0.78 HSP90AA1 (0.64) HSP90AA1HSP90AB1KDM4EHSD17B10ALDH1A1
SCHEMBL5788589 0.77 HSP90AA1 (0.63) HSP90AA1HSP90AB1KDM4EHSD17B10ALDH1A1
SCHEMBL14927263 0.77 HSP90AA1 (0.63) HSP90AA1HSP90AB1KDM4EHSD17B10ALDH1A1
SCHEMBL15399178 0.77 HSP90AA1 (0.62) HSP90AA1HSP90AB1HSD17B10GRM4ATM
Ammonia Solution, Strong SCHEMBL15795498 0.76 HSP90AA1 (0.61) HSP90AA1HSP90AB1KDM4EHSD17B10ALDH1A1
SCHEMBL14930775 0.76 HSP90AA1 (0.61) HSP90AA1HSP90AB1KDM4EHSD17B10ALDH1A1
SCHEMBL151114 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022083657-A1 SUBSTITUTED BENZO OR PYRIDOPYRIMIDINE AMINE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 苏州泽璟生物制药股份有限公司 2022-04-28 WO disclosed
EP-2688870-B1 HETEROCYCLIC AMINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2017-02-01 EP disclosed
CN-103443074-B Heterocyclic amine derivative HOFFMAN-LA ROCHE LTD. (CH) 2016-04-13 CN disclosed
US-8802673-B2 Heterocyclic amine derivatives Hoffmann-La Roche Inc (US) 2014-08-12 US disclosed
EP-2688870-A1 HETEROCYCLIC AMINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2014-01-29 EP disclosed
CN-103443074-A Heterocyclic amine derivatives HOFFMANN LA ROCHE 2013-12-11 CN disclosed
US-20120245172-A1 HETEROCYCLIC AMINE DERIVATIVES HOFFMANN-LA ROCHE INC. 2012-09-27 US disclosed
WO-2012126922-A1 HETEROCYCLIC AMINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2012-09-27 WO disclosed
US-7291645-B2 Phenylalanine derivatives as alpha 4 integrin inhibitors ELAN PHARMACEUTICALS, INC. (US) 2007-11-06 US disclosed
US-7015216-B2 Heteroaryl-β-alanine derivatives as alpha 4 integrin inhibitors ELAN PHARMACEUTICALS, INC. (US) 2006-03-21 US disclosed
CN-1109675-C Aryl pyrimidine derivatives HOFFMANN LA ROCHE (CH) 2003-05-28 CN disclosed
US-20020086882-A1 Heteroaryl-beta-alanine derivatives as alpha 4 integrin inhibitors BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) 2002-07-04 US disclosed
US-20020055509-A1 Phenylalanine derivatives as alpha 4 integrin inhibitors BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) 2002-05-09 US disclosed
US-20020028812-A1 Phenylalanine derivatives CELLTECH CHIROSCIENCE LIMITED (GB) 2002-03-07 US disclosed
US-6348463-B1 Phenylalanine derivatives CELLTECH THERAPEUTICS LIMITED (GB) 2002-02-19 US disclosed
WO-2002008222-A2 HETEROARYL-β-ALANINE DERIVATIVES AS ALPHA 4 INTEGRIN INHIBITORS ELAN PHARMACEUTICALS, INC. (US) 2002-01-31 WO disclosed
WO-2002008206-A1 3-AMINO-2-(4-AMINOCARBONYLOXY)PHENYL-PROPIONIC ACID DERIVATIVES AS ALPHA-4- INTEGRIN INHIBITORS ELAN PHARMACEUTICALS, INC. (US) 2002-01-31 WO disclosed
EP-1117657-A1 PHENYLALANINE DERIVATIVES AS ALPHA 4 INTEGRIN INHIBITORS CELLTECH THERAPEUTICS LIMITED (GB) 2001-07-25 EP disclosed
WO-2000018759-A1 PHENYLALANINE DERIVATIVES AS ALPHA 4 INTEGRIN INHIBITORS CELLTECH THERAPEUTICS LIMITED (GB) 2000-04-06 WO disclosed
CN-1223641-A Aryl pyrimidine derivatives HOFFMANN LA ROCHE (CH) 1999-07-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120245172-A1 HETEROCYCLIC AMINE DERIVATIVES TAAR1, TAAR5, MTNR1A HSP90AA1 869/4885HSP90AB1 807/4885KDM4E 2692/4885
US-20020055509-A1 Phenylalanine derivatives as alpha 4 integrin inhibitors ITGB4, ITGA4, ITGB3 HSP90AA1 3091/4885HSP90AB1 2646/4885KDM4E 469/4885
US-20020086882-A1 Heteroaryl-beta-alanine derivatives as alpha 4 integrin inhibitors ITGAL, ITGB4, ITGA4 HSP90AA1 896/4885HSP90AB1 707/4885KDM4E 2953/4885
US-20020028812-A1 Phenylalanine derivatives PAH, FPR1, VCAM1 HSP90AA1 2061/4885HSP90AB1 1957/4885KDM4E 1423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.